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OBJECTIVE—Exogenous administration of glucagon-like pep-
tide-1 (GLP-1) or GLP-1 receptor agonists such as an exendin-4
has direct beneﬁcial effects on the cardiovascular system. How-
ever, their effects on atherosclerogenesis have not been eluci-
dated. The aim of this study was to investigate the effects of
GLP-1 on accumulation of monocytes/macrophages on the vas-
cular wall, one of the earliest steps in atherosclerogenesis.
RESEARCH DESIGN AND METHODS—After continuous in-
fusion of low (300 pmol  kg
1  day
1) or high (24 nmol  kg
1 
day
1) dose of exendin-4 in C57BL/6 or apolipoprotein E–deﬁ-
cient mice (apoE
/), we evaluated monocyte adhesion to the
endothelia of thoracic aorta and arteriosclerotic lesions around
the aortic valve. The effects of exendin-4 were investigated in
mouse macrophages and human monocytes.
RESULTS—Treatment with exendin-4 signiﬁcantly inhibited
monocytic adhesion in the aortas of C57BL/6 mice without
affecting metabolic parameters. In apoE
/ mice, the same
treatment reduced monocyte adhesion to the endothelium and
suppressed atherosclerogenesis. In vitro treatment of mouse
macrophages with exendin-4 suppressed lipopolysaccharide-
induced mRNA expression of tumor necrosis factor- and
monocyte chemoattractant protein-1, and suppressed nuclear
translocation of p65, a component of nuclear factor-B. This
effect was reversed by either MDL-12330A, a cAMP inhibitor or
PKI14-22, a protein kinase A–speciﬁc inhibitor. In human mono-
cytes, exendin-4 reduced the expression of CD11b.
CONCLUSIONS—Our data suggested that GLP-1 receptor ago-
nists reduced monocyte/macrophage accumulation in the arterial
wall by inhibiting the inﬂammatory response in macrophages,
and that this effect may contribute to the attenuation of athero-
sclerotic lesion by exendin-4. Diabetes 59:1030–1037, 2010
T
he glucagon-like peptide-1 (GLP-1) is a hormone
secreted from the L-cells of the small intestine
and stimulates glucose-dependent insulin re-
sponse (1–3). In addition, GLP-1 has other effects
that may improve the pathophysiology of the diabetic
state, such as suppression of glucagon secretion (2),
inhibition of gastrointestinal secretion and motility (4),
and inhibition of food intake (5). Accordingly, enhance-
ment of GLP-1 actions appears to have ideal proﬁles for
the treatment of type 2 diabetes. However, a single admin-
istration of GLP-1 is not effective as a treatment for
diabetes, because the protein is rapidly degraded by
dipeptidyl peptidase-4. Thus, GLP-1 receptor agonists that
are resistant to dipeptidyl peptidase-4, such as exendin-4,
are currently being used for the treatment of type 2
diabetes.
Given that GLP-1 receptors are abundantly expressed in
many cell types other than pancreatic islet cells, gastroin-
testinal cells, and neural cells, GLP-1 may play wider roles
than expected. Because one of the major objectives of
treatment of type 2 diabetes is to prevent cardiovascular
diseases, several studies investigated the effects of GLP-1
on the cardiovascular system. With regard to the heart,
exogenous administration of GLP-1 and exendin-4 has
direct beneﬁcial effects, such as improvement of left
ventricular performance after myocardial infarction (6,7)
and protection against ischemia (8,9). In cultured human
vascular endothelial cells, one GLP-1 analog inhibited the
expression of tumor necrosis factor- (TNF-) and hyper-
glycemic-mediated induction of expression of plasmino-
gen activator inhibitor type-1 and vascular cell adhesion
molecule-1 (VCAM-1) (10). In vascular endothelial cells,
GLP-1 stimulates NO production, which may explain the
vasodilatory effects in mesenteric arteries (11) and pulmo-
nary artery rings (12). Indeed, it has been demonstrated
that that GLP-1 ameliorates endothelial dysfunction in
type 2 diabetic patients with established coronary artery
disease without affecting whole-body glucose uptake (13).
These data highlight the potential direct protective effects
of GLP-1 on the progression of atherosclerosis. To our
knowledge, however, there is little or no information on
the effects of GLP-1 on atherosclerogenesis.
Atherosclerogenesis is a complex pathologic process
associated with inﬂammatory reactions (14). Monocyte–
endothelial cell interaction plays a crucial role in the
formation of atheroma. Indeed, adhesion of circulating
monocytes to the intimal endothelial cells is considered
one of the earliest events in atherosclerogenesis (15). This
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and their counterreceptors. The endothelially attached
monocytes subsequently invade the vascular wall and play
a central role in inﬂammation of the vascular wall. The
latter process is mediated by several cytokines and che-
mokines secreted by proinﬂammatory macrophages. Thus,
monocytes/macrophages play a pivotal role in atheroscle-
rogenesis. At this stage, the effect of exendin-4 on the roles
of monocytes/macrophages in atherosclerogenesis needs
clariﬁcation.
The present study was designed to determine the effect
of exendin-4 on atherosclerogenesis, with a special focus
on accumulation of monocytes/macrophages in the vascu-
lar wall using en face immunohistochemistry of the endo-
thelial surface in combination with confocal microscopy.
The results indicated that exendin-4 directly suppressed
the progression of atherosclerosis by downregulation of
various inﬂammatory and adhesion molecules on
monocytes/macrophages.
RESEARCH DESIGN AND METHODS
Animals. The study protocol was approved by the Animal Care and Use
Committee of Juntendo University. Male C57BL/6 mice (7 weeks old) were
purchased from Oriental Yeast (Tokyo, Japan) and housed in speciﬁc patho-
gen–free barrier facilities at Juntendo University. Male apolipoprotein E–
deﬁcient (apoE
/) mice (6 weeks old) were purchased from The Jackson
Laboratory (Bar Harbor, ME) and housed in speciﬁc pathogen–free barrier
facilities at the Institute of Nihon Bioresearch (Gifu, Japan). Mice were
maintained under 12-h light/dark cycle, fed a standard rodent diet (from CLEA
Japan at Nihon Bioresearch), and provided with water ad libitum, except
where noted. Mice were treated with either high-dose (24 nmol  kg body
wt
1  day
1) or low-dose (300 pmol  kg body wt
1  day
1) exendin-4
(Sigma-Aldrich, Tokyo, Japan), or with saline through a mini-osmotic pump
(ALZEST, model 1004; DURECT, Cupertino, CA) that delivered the solution
continuously for up to 28 days. At the age of 8 weeks, the osmotic pump was
implanted under the skin of the back of each mouse after local anesthesia. The
skin incision was closed with wound clip.
Preparation of cells and Western blotting analysis. We prepared cell
extracts from various samples. Livers and lungs were isolated from mice and
snap-frozen in liquid nitrogen. Islets were isolated by a standard collagenase
digestion method as described previously (16). Mouse aortic vascular endo-
thelial cells were isolated and cultured as described previously (17). The
cultured cells were veriﬁed as endothelial cells by positive immunostaining
with anti–von Willebrand factor antibody (Dako, Carpinteria, CA) and nega-
tive immunostaining with anti–-smooth muscle actin (Sigma-Aldrich). Mouse
aortic vascular smooth muscle cells were isolated and cultured as described
previously (18). The cultured cells were veriﬁed as smooth muscle cells by
immunostaining using anti–-smooth muscle actin. Peritoneal macrophages
were harvested from the mice with cold PBS at 3 days after intraperitoneal
injection of 3% thioglycolate media. The pooled macrophages from each
mouse were cultured in RPMI 1640, supplemented with 0.2% FCS, 10 mmol/l
HEPES, 1 mmol/l sodium pyruvate, 2 mmol/l L-glutamine, 100 units/ml
penicillin, 100 g/ml streptomycin, and 50 mol/l 2-mercaptoethanol under
95% relative humidity and 5% CO2 at 37°C to allow cell adhesion. Nonadherent
cells were removed by washing with PBS. Human peripheral blood mononu-
clear cells were isolated from whole blood collected from overnight-fasted
healthy volunteers, with Mono-poly Resolving Medium (DS Pharma Biomed-
ical, Osaka, Japan) after heparinization. Monocytes were isolated from
peripheral blood mononuclear cells by positive selection using MACS CD14
microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany). We conﬁrmed
that 95% of the isolated cells were CD14
 monocytes by ﬂow cytometry
analysis. Cells were cultured in RPMI 1640, supplemented with 2% FCS, 10
mmol/l HEPES, 1 mmol/l sodium pyruvate, 2 mmol/l L-glutamine, 100 units/ml
penicillin, 100 g/ml streptomycin, and 50 mol/l 2-mercaptoethanol at 37°C
under a humidiﬁed atmosphere with 5% CO2. THP-1 cells were cultured in
cultured in RPMI 1640, supplemented with 10% FCS, 10 mmol/l HEPES, 1
mmol/l sodium pyruvate, 2 mmol/l L-glutamine, 100 units/ml penicillin, 100
g/ml streptomycin, and 50 mol/l 2-mercaptoethanol under 95% relative
humidity and 5% CO2 at 37°C. Human umbilical vein endothelial cells
(HUVECs) were cultured in 500-ml bottle of endothelial cell basal medium-2
and the following growth supplements: 0.2 ml hydrocortisone, 2 ml human
ﬁbroblast growth factor–basic, 0.5 ml vascular endothelial growth factor, 0.5
ml R3-IGF-1, 0.5 ml ascorbic acid, 0.5 ml heparin, 10 ml FBS, 0.5 ml human
epidermal growth factor, and 0.5 ml GA-1000 (Cambrex BioScience Walkers-
ville, Charles City, IA) under 95% relative humidity and 5% CO2 at 37°C. All
samples were sonicated on ice and centrifuged at 15,000g at 4°C for 20 min.
The supernatants were collected and Western blot analysis was performed
using anti–GLP-1R antibody (ab3907; Abcam, Cambridge, U.K.) or rabbit
anti–glyceraldehyde-3-phosphate dehydrogenase antibody (Cell Signaling
Technology, Beverly, MA) as described previously (16).
IPGTT and insulin tolerance test. The intraperitoneal glucose tolerance
test (IPGTT) was performed at the age of 12 weeks (4 weeks after implanta-
tion of the osmotic pump). Brieﬂy, 1.0 g/kg body wt glucose was injected
intraperitoneally after overnight fasting. Blood glucose level was measured
with a glucometer (One-Touch Ultra; Life Scan, Burnaby, Canada). Plasma
insulin levels were measured using an ELISA kit (Morinaga, Kanagawa,
Japan). The insulin tolerance test was performed at the age of 12 weeks with
0.75 units/kg body wt insulin (Humalin; Eli Lilly, Indianapolis, IN) after6ho f
fasting. Blood samples were collected from the retro-orbital venous plexus in
awake mice to measure blood glucose and plasma insulin concentrations.
Immunohistochemistry. After mice were killed by intraperitoneal injection
of sodium pentobarbital (1 mg/kg; Abbott Laboratories), tissue preparation
was performed by systemic perfusion with saline and 10% buffered formalin.
Fixation was performed by immersion of the isolated thoracic aorta with 10%
buffered formalin at 4°C. For en face immunohistochemistry of the endothelial
surface, the thoracic aorta was cut open longitudinally along the ventral side
with scissors and placed on a glass slide. Then immunohistochemistry was
performed using anti-mouse Mac-2 monoclonal antibody (Dako, Cederlane,
Burlington, ON, Canada). Next, each specimen was placed on a slide glass
with the intimal side up, and covered with a coverslip. Specimens were viewed
under a microscope (E800; Nikon, Tokyo, Japan) connected to an XYZ
controller and a digital camera (Sony, Tokyo, Japan). To count the number of
endothelium-adherent monocytes, we set a rectangular area with sides that
were twice the length of the long and short diameters of the vessel opening of
the intracostal arteries, respectively, and that were centered on the opening.
The total number of Mac-2–immunopositive cells within the entire rectangular
areas were counted in each aorta. The cell density in each area was then
calculated as the cell count (determined by an examiner blinded to the
treatment regimen) divided by the total area (19–21).
For ﬂuorescent staining, the samples were embedded in optimal cutting
temperature compound, then sectioned, air dried, and washed in PBS. After
immersion in blocking solution of 10% goat serum in PBS for 30 min at room
temperature, the sections were incubated overnight at 4°C in a humidiﬁed
chamber for labeling with rabbit polyclonal anti-GLP1 receptor antibody (1:50,
LS-A1205; MBL International, Woburn, MA), and rabbit anti–Mac-2 monoclo-
nal antibody (1:200; Dako). The specimens were placed in the appropriate goat
secondary antibody conjugated with Alexa Fluor Dyes (Invitrogen, Carlsbad,
CA) and diluted 1:300 in PBS for 30 min at room temperature. The specimen
was placed on a glass slide, DAPI-containing mounting medium (Vector
Laboratories, Burlingame, CA) was added, and then the tissue was covered
with a cover glass. Samples were viewed by confocal laser scanning micros-
copy (Fluoview FV1000; Olympus, Tokyo, Japan).
Quantiﬁcation of atherosclerotic lesions in the aortic sinus. The heart
and the aorta were ﬂushed with normal saline followed by 10% buffered
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FIG. 1. Expression of GLP-1 receptor on macrophages. A: Expression of
GLP-1 receptor in murine lung and liver, isolated murine islets, iso-
lated murine macrophages (Ms), cultured murine endothelial cells
(ECs), cultured murine smooth muscle cells (SMCs), human monocyte
derived line, THP-1 cells, and HUVECs. B: Expression of GLP-1 recep-
tor in human monocytes from healthy subjects. C: Immunohistochem-
ical staining of GLP-1 receptor (green) and Mac-2, a marker of
macrophages (red) in atherosclerotic lesions of apoE
/ mice. (A
high-quality digital representation of this ﬁgure is available in the
online issue.)
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rotic lesions in the aortic sinus, the heart was cut in two halves and the top
half was embedded in optimal cutting temperature compound, then cross-
sectioned at 4-m thickness at 50-m interval with a cryostat. Twelve
consecutive sections were taken sequentially from just above the aortic valve
throughout the aortic sinus and allowed to dry at room temperature for 30
min. Sections were stained with oil red O staining as described above. Then,
the images were captured with ImagePro Plus software. The mean lesion area
of those 12 sections was calculated and expressed in square millimeters.
Ex vivo treatment of macrophages. The isolated macrophages were
washed once and then incubated with or without 0.03, 0.3, and 3 nmol/l
exendin-4 or 10 mol/l forskolin (an adenylate cyclase activator; Sigma-
Aldrich) for 1 h, followed by incubation with or without lipopolysaccharide
(LPS, 1 g/ml; Sigma-Aldrich) for 1 h. To inhibit the exenatide signal,
macrophages were incubated with 5 mol/l MDL-12330A (Sigma-Aldrich), a
speciﬁc adenylate cyclase inhibitor, and 10 mol/l PKI14-22 (Sigma-Aldrich), a
protein kinase A (PKA) inhibitor, for 30 min before adding exendin-4. Control
macrophages were incubated with the vehicle (DMSO, ﬁnal concentration
0.1%). After treatment, total RNA was prepared for further analysis. Nuclear
protein extracts were isolated from peritoneal macrophages and the content
of nuclear factor-B (NF-B) p65 was determined using a speciﬁc ELISA kit
using the method recommended by the manufacturer (Imgenex, San Diego,
CA) (22).
Isolation of tissue RNA and real-time quantitative RT-PCR. Total RNA
was extracted from peritoneal macrophages using the RNA easymicro Kit
(Qiagen, Tokyo, Japan) and the instructions provided by the manufacturer.
First-strand cDNA was synthesized using 1 g of total RNA with oligo-dT
primers and superscript reverse transcriptase (Invitrogen) as described pre-
viously (23). The resulting cDNAs were ampliﬁed using the SYBR Green PCR
kit (Applied Biosystems, Foster City, CA). Quantitative PCR was performed
with an ABI Prism 7700 sequence detection system (Perkin Elmer Life
Sciences, Boston, MA). The relative abundances of mRNAs were calculated by
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FIG. 2. Exendin-4 reduced monocytic adhesion to the endothelium in C57BL/6 mice. A: Changes in body weight during treatment with exendin-4
in C57BL/6 mice (n  6 each). B: Blood glucose concentrations during IPGTT after 24-day treatment with exendin-4 (n  6 each). C: Plasma
insulin levels during IPGTT after 24-day treatment with exendin-4 (n  6 each). D: Results of insulin tolerance test in each group after 24-day
treatment with exendin-4 (n  6 each). E: The density of adherent Mac-2–positive cells on endothelial cells at branching areas in each group of
mice after 28-day treatment (n  6) with representative en face views of immunohistologic staining with Mac-2 antibody. Data are mean  SEM.
*P < 0.05 versus high-dose group, P < 0.05 versus low-dose group. (A high-quality digital representation of this ﬁgure is available in the online
issue.)
EXENDIN-4 AND ATHEROSCLEROGENESIS
1032 DIABETES, VOL. 59, APRIL 2010 diabetes.diabetesjournals.orgthe comparative cycle of threshold method with TATA box–binding protein
for mice as the invariant control.
Flow cytometry. After collection and stabilization for 6 h, monocytes were
cultured in the presence or absence of different concentrations of exendin-4
for 24 h. The culture supernatants were removed and cells washed with PBS
to remove nonadherent cells. Adherent monocytes were collected by scraping
with a plastic policeman and pipetting. The Fc receptors were blocked by
Clear Back (human Fc receptor blocking reagent; MBL, Nagoya, Japan) for 5
min at room temperature. Then the cells were stained with phycoerythrin–
labeled antibodies to anti-human CD11b or the corresponding isotype control
(nonspeciﬁc mouse IgG-phycoerythrin) (BD Biosciences, Cologne, Germany)
and incubated at 4°C for 15 min. Flow cytometry was performed on a Becton
Dickinson FACScan System. Data were expressed as mean ﬂuorescence
intensities, relative to the control.
Data analysis. All data are presented as mean  SEM. Differences among
multiple groups were analyzed by one-way ANOVA. Bonferroni multiple
comparison test was used for comparisons among multiple treatment groups
and the control group. A P value less than 0.05 denoted the presence of a
statistically signiﬁcant difference.
RESULTS
GLP-1 receptor is abundantly expressed in mono-
cytes/macrophages. As a ﬁrst step to elucidate the anti-
atherosclerotic effects of exendin-4, we ﬁrst investigated
the expression of GLP-1 receptor in cells associated with
atherosclerogenesis. Similar to lung and pancreatic -cells
(24), mice peritoneal macrophages and vascular smooth
muscle cells abundantly expressed GLP-1 receptor pro-
tein, and the expression level was higher than in freshly
isolated endothelial cells. Similar to the expression level in
macrophages, GLP-1 receptor was abundantly expressed
in THP-1 cells, which are derived from human monocytes,
and freshly isolated human monocytes. In contrast to the
freshly isolated endothelial cells, abundant expression of
GLP-1 receptor was detected in HUVECs (Fig. 1A and B).
In addition, immunohistochemical staining showed GLP-1
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FIG. 3. The metabolic effect of exendin-4 in apoE
/ mice. A: Changes in body weight during exendin-4 treatment in apoE
/ mice (n  13). B:
Blood glucose concentrations during IPGTT after 24-day treatment with exendin-4 (n  6). C: Plasma insulin levels during IPGTT after 24-day
treatment with exendin-4 (n  6). D: Results of insulin tolerance test in each group after 24-day treatment with exendin-4 (n  6). Data are
mean  SEM. *P < 0.01 versus high-dose group, P < 0.01 versus low-dose group.
TABLE 1
Results of laboratory tests in C57BL/6 mice and apoE
/ mice after 28-day treatment with exendin-4
C57BL/6 ApoE
/
Control Low Ex4 High Ex4 Control Low Ex4 High Ex4
Total cholesterol (mg/dl) 66.7  2.6 70.5  1.4 73.9  2.2* 522.3  26.3 472.6  22.8 437.2  30.0*
LDL cholesterol (mg/dl) 6.62  0.42 6.33  0.25 7.30  0.59 136.5  8.2 126.4  7.5 138.4  4.9
HDL cholesterol (mg/dl) 56.6  2.0 61.0  1.2 63.3  1.5* 16.9  0.8 16.1  1.0† 19.0  0.9
TGs (mg/dl) 42.9  4.4 41.3  3.3 37.6  5.9 52.7  4.2 54.7  4.1 62.3  4.2
CM (mg/dl) 5.95  1.02 7.24  1.13 4.35  1.02 63.9  4.4 61.6  2.3 55.5  4.2
Sd-LDL (mg/dl) 1.18  0.07 1.16  0.04 1.22  0.09 27.0  1.7 25.3  1.7 29.2  1.1
A1C (%) NA NA NA 3.46  0.20 3.64  0.17 3.38  0.12
Data are mean  SE. Blood samples were collected from C57BL/6J mice (n 	 6) and apoE
/ mice (n 	 13 except for HbA1C, n 	 6 for
HbA1C) in the fasting state after 28-day treatment with exendin-4. *P  0.05 vs. control group. †P  0.05 for low Ex4 vs. high Ex4. Low Ex4,
low-dose exendin-4; High Ex4, high-dose exendin-4; TG, triglycerides; CM, chylomicron; Sd-LDL, small, dense LDL; HbA1c, A1C; NA, not
applicable.
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marker of macrophages located in the atherosclerotic
lesions of the aortic valve of apoE
/ mice (Fig. 1C).
These results may suggest that GLP-1 can directly act on
monocytes or macrophages and affect the progression of
atherosclerosis.
Exendin-4 reduces monocyte adhesion in C57BL/6
mice without affecting glucose tolerance. To investi-
gate the effect of GLP-1 receptor activation on atheroscle-
rosis, C57BL/6 mice received continuous infusion of 300
pmol  kg
1  day
1 (low dose) or 24 nmol  kg
1  day
1
(high dose) exendin-4 for 28 days. During the treatment
period, neither dose affected body weight (Fig. 2A). After
the 24-day treatment, both doses of exendin-4 improved
glucose tolerance without affecting insulin secretion (Fig.
2B and C). The results of the insulin tolerance test were
similar in the two groups (Fig. 2D). Treatment with
high-dose exendin-4, but not the low dose, slightly in-
creased total cholesterol and HDL cholesterol compared
with control group (Table 1). The density of monocytes
that adhered to the endothelial cells of the thoracic aorta
was markedly suppressed in both the low- and high-dose
treatment groups, compared with control (Fig. 2E).
Exendin-4 reduces monocyte adhesion and athero-
sclerotic lesions in apoE
/ mice. To explore the role of
GLP-1 receptor activation on the progression of athero-
sclerosis, we treated apoE
/ mice with low- or high-dose
exendin-4. Treatment with high-dose exendin-4 modestly
reduced body weight gain and glucose tolerance and
decreased serum total cholesterol level without affecting
LDL cholesterol level (Fig. 3, Table 1). On the other hand,
treatment with low-dose exendin-4 only modestly reduced
glucose level at 30 min after glucose injection without
affecting other parameters investigated (Fig. 3, Table 1).
The density of monocytes that adhered to endothelial cells
of the thoracic aorta was signiﬁcantly lower in the low-
and high-dose groups than the control group (Fig. 4A).
Quantiﬁcation of mRNA expression in the thoracic aorta
showed that exendin-4 treatment signiﬁcantly downregu-
lated intercellular adhesion molecule-1 (ICAM-1) and
tended to downregulate VCAM-1 (Fig. 4B). In parallel with
the decreased monocyte adhesion to endothelial cells, the
oil red O–positive area at the aortic valve level was
signiﬁcantly reduced in the high-dose group compared
with the control group (Fig. 4C). The area of the athero-
sclerotic lesions in the low-dose group also tended to be
smaller than the control group, however the difference
was not signiﬁcant.
Exendin-4 reduces the inﬂammatory response
through cAMP signaling pathway in macrophages. The
data obtained from apoE
/ mice and C57BL/6 mice
suggested that exendin-4 could have beneﬁcial effects
against atherosclerosis without affecting the metabolic
parameters and that it could potentially prevent the pro-
gression of atherosclerosis by its direct action on the cells
involved in atherosclerogenesis. The abundant expression
of GLP-1 receptor in monocytes/macrophages and the
inhibitory effects of exendin-4 on monocyte adhesion on
endothelial cells encouraged us to investigate the effects of
exendin-4 on the inﬂammatory response.
LPS is known to induce inﬂammatory response. Indeed,
incubation with 1 g/ml of LPS for 1 h induced 
10-fold
increases in the expression levels of TNF- and monocyte
chemoattractant protein-1 (MCP-1), a representative cyto-
kine and a chemokine in isolated macrophages, respec-
tively (data not shown). Thus, we investigated the effects
of various concentrations of exendin-4 (0.03–3 nmol/l) in
counteracting this response. Exendin-4 at all concentra-
tions signiﬁcantly suppressed LPS-induced increases in
the expression levels of TNF- and MCP-1 in macrophages
(Fig. 5A). GLP-1 receptor is well-known Gs-protein–cou-
pled receptor, thus the activation of GLP-1 receptor results
in increased cAMP concentration due to activation of
adenylate cyclase (25). To explore the mechanism of
exendin-4–induced suppression of TNF- and MCP-1 ex-
pression in macrophages, we preincubated peritoneal
macrophages with MDL-12330A, a speciﬁc adenylyl cy-
clase inhibitor, or forskolin, an adenylyl cyclase activator.
The addition of MDL-12330A completely suppressed the
inhibitory effect of exendin-4 on the expression levels of
TNF- and MCP-1 (Fig. 5B). On the other hand, forskolin
signiﬁcantly suppressed LPS-induced TNF- and MCP-1
expression in macrophages, and the levels of suppression
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FIG. 4. Exendin-4 reduced monocyte adhesion to the endothelium and
atherosclerotic lesions in apoE
/ mice. A: En face immunohistochem-
ical staining with Mac-2 antibody of the aorta of each group. The
density of adherent Mac-2–positive cells on the endothelium at branch-
ing areas in each group of mice after 28-day treatment (n  7) and
representative en face views of immunohistologic staining with Mac-2
antibody. B: Aortas harvested from each group of mice after 28-day
treatment were used for isolation of total RNA. The mRNA expression
levels of ICAM-1 and VCAM-1 were determined by quantitative RT-
PCR. Relative gene expression is displayed as the level of expression in
the test mice relative to that in the control group (set at 1.0, n  5–7).
C: Representative histologic sections of the aortic sinuses stained with
oil red O after 28-day treatment. The mean area of oil red O–positive
lesions was determined (n  20). Data are mean  SEM. *P < 0.05
versus control group. (A high-quality digital representation of this
ﬁgure is available in the online issue.)
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These results suggest that the inhibitory effects of ex-
endin-4 on the expression of TNF- and MCP-1 are largely
dependent on the activation of adenylate cyclase. Next, we
investigated the downstream pathway of cAMP using
PKI14-22, a speciﬁc PKA inhibitor. Similar to MDL-12330A,
the inhibitory effect of exendin-4 was signiﬁcantly re-
versed by PKI14-22 (Fig. 5D), suggesting the involvement of
PKA in the anti-inﬂammatory effect of exendin-4.
Although NF-B is a major regulator of the expression
of TNF- and MCP-1, vasoactive intestinal peptide and
pituitary adenylate cyclase–activating polypeptide are
known to inhibit NF-B–dependent gene activation by
activation of PKA in cultured monocytic cell line THP-1
(26). Thus, we investigated the effect of exendin-4 on
LPS-induced nuclear translocation of NF-B p65 in mac-
rophages. Without any stimulation, nuclear NF-B p65 was
not detected in peritoneal macrophages, however, stimu-
lation with LPS robustly induced nuclear translocation of
NF-B p65 (data not shown). Such translocation was
markedly suppressed by exendin-4, and this inhibitory
effect was completely abolished by MDL-12330A (Fig. 5E).
These results indicate that exendin-4 inhibits nuclear
translocation of NF-B p65 by activating cAMP, in parallel
with the expression of TNF- and MCP-1.
Finally, we investigated the effect of exendin-4 on hu-
man monocytes. As stated above, exendin-4 attenuated the
expression of ICAM-1 in apoE
/ mice. Thus, we investi-
gated the effects of exendin-4 on their counterreceptors,
CD11b, in isolated human peripheral monocytes. Expo-
sure to 0.3 and 3 nmol/l, but not 0.03 nmol/l, exendin-4 for
24 h signiﬁcantly reduced the surface expression of
CD11b, as assessed by ﬂow cytometry (Fig. 5F). These
results suggest that activation of the GLP-1 receptor has
the antiatherogenic effects on human circulating
monocytes.
DISCUSSION
In the present study, we provide evidence that exendin-4,
a GLP-1 receptor agonist, prevents the progression of
atherosclerosis in apoE
/ mice without major effects on
metabolic parameters. Our data suggest that exendin-4
markedly reduced the accumulation of monocytes/macro-
phages in the vascular wall at least in part by suppressing
the inﬂammatory response in macrophages through the
activation of the cAMP/PKA pathway.
The results showed that the exendin-4 decreased mono-
cyte adhesion to endothelial cells in two nondiabetic mice,
C57BL6 and apoE
/ mice. In both mouse strains, ex-
endin-4 reduced glucose level during IPGTT, however,
because the two strains are nondiabetic, the effect of
exendin-4 on glucose level should play only a minor effect
on its antiatherosclerogenetic properties.
In this study, we conﬁrmed the expression of GLP-1
receptor in endothelial cells, smooth muscle cells, macro-
phages, and monocytes. Because these cells play critical
roles in the progression of atherosclerosis, GLP-1 receptor
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FIG. 5. Exendin-4 reduced the inﬂammatory response through cAMP signaling pathway in macrophages, and reduced the expression of CD11b in
human monocytes. A: Peritoneal macrophages isolated from 8-week-old C57BL/6 mice were incubated with various concentrations of exendin-4
(0.03–3 nmol/l) for 1 h followed by treatment with LPS (1 g/ml) for 1 h. Then, macrophages were used for isolation of total RNA. The mRNA
expression levels of TNF- and MCP-1 were determined by quantitative RT-PCR. Relative gene expression is displayed as the level of expression
in peritoneal macrophages without the addition of exendin-4 set at 1.0 (n  4–5). B: Peritoneal macrophages were preincubated with 5 mol/l
MDL-12330A for 30 min before the addition of 0.3 nmol/l exendin-4 and then incubated with LPS (1 g/ml) for 1 h. Then, macrophages were used
for isolation of total RNA (n  4–6). C: Peritoneal macrophages were incubated with 0.3 nmol/l exendin-4 or 10 mol/l forskolin for 1 h followed
by LPS (1 g/ml) for 1 h. Then, macrophages were used for isolation of total RNA (n  4–5). D: Peritoneal macrophages were preincubated with
10 mol/l PKI14-22 for 30 min before the addition of 0.3 nmol/l exendin-4 and then incubated with LPS (1 g/ml) for 1 h. Then, macrophages were
used for isolation of total RNA (n  4–5). E: Peritoneal macrophages were preincubated with 5 mol/l MDL-12330A for 30 min before the addition
of 0.3 nmol/l exendin-4 and then incubated with LPS (1 g/ml) for 1 h. Then, macrophages were used for isolation of nuclear protein extracts. The
nuclear level of NF-B p65 was determined by enzyme-linked immunosorbent assay (ELISA) (n  3–4). F: Human monocytes isolated from
healthy volunteers were incubated without or with various concentrations of exendin-4 (0.03–3 nmol/l) for 24 h. Then, the surface expression of
CD11b was assessed by ﬂow cytometry. Data are median ﬂuorescence intensity relative to the control. *P < 0.05 versus the control group.
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genesis. Indeed, several groups reported the beneﬁcial
effects of GLP-1 receptor activation on endothelial cells
(10–13). On the other hand, we conﬁrmed in the present
study the direct anti-inﬂammatory effect of GLP-1 on
monocytes/macrophages. Indeed, treatment with ex-
endin-4 at concentrations observed during treatment of
humans (27,28) reduced the expression of inﬂammatory
mediators TNF- and MCP-1 in activated macrophages.
TNF- and MCP-1 are among the important cytokines and
chemokines whose atherogenic effect has been estab-
lished. Both TNF-– and MCP-1–deﬁcient mice have sig-
niﬁcantly reduced atherosclerotic lesions (29,30).
Furthermore, forced expression of TNF- and MCP-1 in
leukocytes promotes advanced atherosclerotic lesions
(29,31). Thus, in addition to the effect of GLP-1 on endo-
thelial cells, its effect on monocytes/macrophages may
also have a major impact on the attenuation of
atherosclerosis.
It was reported previously that the main effects of GLP-1
are mediated through the activation of adenylate cyclase
and the production of cAMP (25). Using adenylate cyclase
inhibitor and activator, we also demonstrated in this study
that stimulation of cAMP by exendin-4 is critical for the
attenuated production of proinﬂammatory mediators from
macrophages. This result is consistent with previous stud-
ies in which increased intracellular levels of cAMP inhib-
ited TNF- production and its transcription in macrophage
(32–34). These data suggest that exendin-4 regulates in-
ﬂammatory response of macrophages via the cAMP/PKA
pathway, which inhibits proinﬂammatory cytokine pro-
duction as reported recently (35,36). Our results showed
that PKA activation and inhibition of NF-B p65 translo-
cation mediate overexpression of inﬂammatory cytokines
by increased cAMP level elicited by GLP-1 receptor
activation.
The adhesion of circulating monocytes to the intimal
endothelial cells is thought to be one of the earliest events
in the complex pathologic process of atherosclerogenesis
(14,15). This can be mediated by the interaction of speciﬁc
adhesion molecules on vascular endothelial cells with
their integrin counterreceptors on monocytes. CD11b is an
important adhesion molecule on monocytes. Activation of
monocytes by cytokines, chemokines, hypercholesterol-
emia, and hyperglycemia leads to increased expression of
this integrin, and increased monocyte expression of
CD11b correlates with adhesion of these cells to the
endothelium in patients with hypercholesterolemia (37).
Our results showed a potential suppressive effect of ex-
endin-4 on the surface expression of CD11b on human
monocytes. On the other hand, we demonstrated that
exendin-4 decreased the expression of ICAM-1, which
interacts with CD11b on monocytes in apoE
/ mice.
These effects may contribute at least in part to the
reduced monocyte adhesion to the endothelium in vivo.
However, additional experiments are required to clarify
the mechanism of exendin-4–induced inhibition of
CD11b expression.
In conclusion, our data suggest that GLP-1 receptor
activation signiﬁcantly reduced the accumulation of mono-
cytes/macrophages in the vascular wall and eventually
inhibited atherosclerogenesis by regulating inﬂammation
in macrophages via the cAMP/PKA pathway and the
integrin-related gene expression on monocytes. These
unique effects of GLP-1 receptor activation may help
design new therapies for cardiovascular disease in pa-
tients with type 2 diabetes.
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